Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore
Authors
Keywords
-
Journal
Expert Review of Pharmacoeconomics & Outcomes Research
Volume -, Issue -, Pages 1-8
Publisher
Informa UK Limited
Online
2021-02-19
DOI
10.1080/14737167.2021.1880323
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
- (2020) Sandra M Swain et al. LANCET ONCOLOGY
- Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer
- (2020) Mohamed Ismail Abdul Aziz et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
- (2020) Lee Cheng Phua et al. BMC HEALTH SERVICES RESEARCH
- A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology
- (2020) Holly Cranmer et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-Effectiveness Analysis of Pertuzumab with Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States
- (2019) Louis P. Garrison et al. VALUE IN HEALTH
- Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology
- (2019) D. Dankó et al. HEALTH POLICY
- A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan
- (2019) Vakaramoko Diaby et al. BREAST
- Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective
- (2018) Ping-Tee Tan et al. BMC CANCER
- Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States
- (2016) Vakaramoko Diaby et al. BREAST CANCER RESEARCH AND TREATMENT
- Ten-year survival in women with primary stage IV breast cancer
- (2016) Lee Guek Eng et al. BREAST CANCER RESEARCH AND TREATMENT
- Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2016) Ben Y. Durkee et al. JOURNAL OF CLINICAL ONCOLOGY
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now